Next report date
Report period
Q2 2024
EPS estimate
—
Revenue estimate
—
−1.05CNY
−70.99 MCNY
132.50 MCNY
92.55 M
About JIANGSU GDK BIOLOGICAL TECHNOLOGY
Sector
Industry
CEO
Jian Hui Zhang
Website
Headquarters
Taizhou
Employees (FY)
451
Founded
2008
ISIN
CNE100004NR4
FIGI
BBG00Y009ZC4
Jiangsu gdk Biotechnology Co., Ltd. engages in the research and development, production and sale of human vaccines. Its products include freeze-dried human rabies, quadrivalent influenza virus, 23-valent pneumococcal polysaccharide, freeze-dried live attenuated varicella, freeze-dried live attenuated herpes zoster, 13-valent pneumococcal polysaccharide conjugate and recombinant shingles vaccines. The company was founded by Yun De Hou and Jing Zhao on December 29, 2008 and is headquartered in Taizhou, China.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 688670 is 16.91 CNY — it has increased by 0.48% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on SSE exchange JIANGSU GDK BIOLOGICAL TECHNOLOGY stocks are traded under the ticker 688670.
JIANGSU GDK BIOLOGICAL TECHNOLOGY is going to release the next earnings report on Aug 5, 2024. Keep track of upcoming events with our Earnings Calendar.
688670 stock is 3.57% volatile and has beta coefficient of 1.92. Check out the list of the most volatile stocks — is JIANGSU GDK BIOLOGICAL TECHNOLOGY there?
Yes, you can track JIANGSU GDK BIOLOGICAL TECHNOLOGY financials in yearly and quarterly reports right on TradingView.
688670 stock has risen by 0.36% compared to the previous week, the month change is a 9.57% fall, over the last year JIANGSU GDK BIOLOGICAL TECHNOLOGY has showed a 59.50% decrease.
688670 net income for the last quarter is −21.49 M CNY, while the quarter before that showed −59.91 M CNY of net income which accounts for 64.13% change. Track more JIANGSU GDK BIOLOGICAL TECHNOLOGY financial stats to get the full picture.
Today JIANGSU GDK BIOLOGICAL TECHNOLOGY has the market capitalization of 2.07 B, it has increased by 0.12% over the last week.
Yes, 688670 dividends are paid annually. The last dividend per share was 0.20 CNY. As of today, Dividend Yield (TTM)% is 0.61%. Tracking JIANGSU GDK BIOLOGICAL TECHNOLOGY dividends might help you take more informed decisions.
Like other stocks, 688670 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade JIANGSU GDK BIOLOGICAL TECHNOLOGY stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 27, 2024, the company has 451.00 employees. See our rating of the largest employees — is JIANGSU GDK BIOLOGICAL TECHNOLOGY on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So JIANGSU GDK BIOLOGICAL TECHNOLOGY technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating JIANGSU GDK BIOLOGICAL TECHNOLOGY stock shows the sell signal. See more of JIANGSU GDK BIOLOGICAL TECHNOLOGY technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.